NS
Article DetailSEC EDGAR Filings
首页文档检索台
SEC EDGAR Filings

8-K - BridgeBio Oncology Therapeutics, Inc. - 5.02 / 7.01 / 9.01

Filed: 2026-04-23 AccNo: 0001193125-26-170888 Size: 184 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
查看原文来源主页查看事件簇按来源查看
发布时间04/22 21:31 UTC
首次发现04/23 10:05 UTC
热度79.4
重要度84
情绪-0.02

站内整理正文

优先显示结构化正文；如果正文还未抽出，则回退到摘要。
sec_edgar_index_v1 · 889 字符

Form 8-K - Current report: SEC Accession No. 0001193125-26-170888

Filing Date: 2026-04-23

Accepted: 2026-04-22 17:31:11

Documents: 13

Period of Report: 2026-04-20

Items: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

BridgeBio Oncology Therapeutics, Inc. (Filer) CIK : 0001869105 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41955 | Film No.: 26884859 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)

1 | 8-K | d253464d8k.htm iXBRL | 8-K

2 | EX-99.1 | d253464dex991.htm | EX-99.1

6 | GRAPHIC | g253464dsp5.jpg | GRAPHIC

3 | XBRL TAXONOMY EXTENSION SCHEMA | bbot-20260420.xsd | EX-101.SCH